$23.500
0.000 (0.00%)At close
CTEV News
CTEV Events
Claritev Selected to Support World Trade Center Health Program
Claritev Corporation has been selected by General Dynamics Information Technology to support the World Trade Center Health Program. The WTC Health Program is a limited federal health care program established under the James Zadroga 9/11 Health and Compensation Act of 2010. It provides nationwide medical monitoring and treatment to responders and survivors of the events of September 11, 2001. As part of GDIT's team, Claritev will leverage its existing provider network to administer the Nationwide Provider Network, ensuring members across the country have access to available, high-quality healthcare. Claritev's extensive network will connect Survivors and Responders who reside outside of the New York metropolitan area with healthcare providers experienced in diagnosing and treating unique conditions related to 9/11 exposures.
Claritev Appoints Ben Letham as Director
Claritev (CTEV) announced that its Board of Directors has appointed Ben Letham as a director, effective September 14, 2026, to fill a vacancy on the Board. Letham currently serves as a research scientist at Meta (META).
Claritev Q2 Revenue Reaches $257.48M, Exceeds Expectations
Reports Q2 revenue $257.48M, consensus $244.81M. "Claritev once again demonstrated the strength of our vision and strategy in the second quarter of 2026, delivering financial results above expectations with solid execution across the company. We are one year into a transformation program that has seen our company operate with greater clarity, alignment, and focus. This transformation is most notably highlighted by a broader portfolio of solutions, expanded vertical sales markets, heightened focus on AI as both an operational and innovation lever, and a company-wide focus on execution that is building a foundation for long term, sustainable, and ultimately faster growth," said Travis Dalton, Chairman, CEO and President of Claritev.
Company Raises FY26 Adjusted EBITDA Outlook to $620M
Consensus $993.39M. Raises FY26 adjusted EBITDA view to $620M-$620M from $605M-$615M. Backs FY26 capital expenditures view $160M-$170M. Dalton added, "This success is most clearly reflected in our bookings which were spread across solutions and verticals, with notable strength in the TPA market where we closed several seven-figure transactions. With more than $70 million in bookings through the first half of 2026, we are well on our way to achieving our full year target of $100 million which would represent 50% growth over 2025 and is a leading indicator of continued growth in 2027 and beyond."
DOJ Expands Antitrust Investigation into Claritev
DOJ expands Claritev antitrust investigation, Bloomberg reports
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.



